Healthcare
Deal focus: IMM overcomes distancing disruption
Health and safety was a priority when IMM Private Equity negotiated a $413 million carve-out of Korea Kolmar Holdings' drug outsourcing business against the backdrop of COVID-19
Hillhouse leads $160m Series B for China's Genor Biopharma
Genor Biopharma, a Shanghai-based innovative drug developer, has raised $160 million in Series B funding led by Hillhouse Capital.
Shiyu leads $276m round for China's Mabwell Biotech
Mabwell Biotech, a Chinese drug developer with one treatment cleared for production, has raised RMB1.97 billion ($276 million) in Series A funding across two tranches led by specialist healthcare investor Shiyu Capital.
Sequoia leads $30m round for China's Atom Bioscience
Chinese drug developer Jiangsu Atom Bioscience & Pharmaceutical has raised $30 million in Series B funding led by Sequoia Capital China and Hong Kong-listed Livzon Pharmaceutical Group.
MGI Tech closes China's largest-ever genetics funding round
MGI Tech, a Chinese manufacturer of gene sequencing devices, has raised more than $1 billion in funding led by IDG Capital and CPE.
IMM agrees $413m Korea pharma acquisition
IMM Private Equity has agreed to acquire Korea Kolmar Holdings’ pharmaceutical contract development and manufacturing organization (CDMO) for KRW512.5 billion ($413 million).
China’s Burning Rock Biotech files for US IPO
Burning Rock Biotech, a venture capital-backed, China-based provider of genetic testing services used in cancer diagnosis, has filed for an IPO in the US.
PE-backed Kintor Pharma raises $240m in Hong Kong IPO
Kintor Pharmaceutical, a Chinese drug developer backed by the likes of HighLight Capital and Shenzhen Green Pine Capital Partners, posted a 7% gain on debut following a HK$1.86 billion ($240 million) Hong Kong IPO.
EQT faces legal action after scrapping NZ aged care deal
New Zealand retirement village operator Metlifecare has filed legal action aimed at forcing EQT Partners to fulfill an acquisition that it decided to terminate due to COVID-19.
Zentalis raises $20m for China drug development venture
Zentalis Pharmaceuticals, a US cancer treatment specialist that raised $165 million in an IPO last month, has secured $20 million in funding to establish a China-based joint venture.
Optum, Health Catalyst back Singapore's Holmusk
US investors Optum Ventures and Health Catalyst Capital have co-led a $21.5 million Series A round for Singapore-based healthcare technology developer Holmusk.
Hong Kong ups disclosure requirements for biotech IPOs
The Hong Kong Stock Exchange has tightened disclosure requirements for companies looking to take advantage of two-year-old reforms permitting listings by pre-revenue biotech companies.
Japan biotech player raises $25m Series B
Japanese biotech developer Modulus Discovery has raised $25.5 million in Series B funding from a group of local VCs including SBI Investment.
Gaorong leads Series A for Chinese gene sequencing player
Qitan Technology, a Chinese gene sequencing company, has raised RMB100 million ($14 million) in Series A funding led by Gaorong Capital. Other backers include Yinxinggu Capital and Yahui Preision Medical Fund.
Intel Capital backs three Chinese start-ups
Intel Capital has invested in two Chinese semiconductor suppliers and a Chinese medical technology developer as part of a $132 million commitment spread across 11 start-ups.
Hummingbird Bioscience gets $25m extended Series B
Hummingbird Bioscience, a Singapore and US-based drug developer with two cancer treatments on course to enter clinical trials, has received $25 million in an extended Series B round of funding led by the holding company of Korea’s SK Group.
Carlyle pursues control of India's SeQuent for $210m
The Carlyle Group has reached agreements that could see it pay INR16.3 billion ($216 million) for up to 74% of Indian animal healthcare services provider SeQuent Scientific.
Bain makes $1b bid for Japan care services provider
Bain Capital has submitted a buyout offer for Nichii Gakkan, a Tokyo-listed provider of aged care, childcare and medical support services, that values the company at approximately JPY109.5 billion ($1 billion).
CVC to invest in Indian cancer care chain operator
CVC Capital Partners plans to acquire 36.4% of HealthCare Global Enterprises (HCG) in a deal that ultimately could see it assume majority ownership of the Indian cancer care center operator.
Hamilton Lane backs Polaris-led privatization of Japan's Sogo Medical
Hamilton Lane has participated as a co-investor in a Japanese take-private for the first time, supporting a Polaris Capital Group-led tender offer for Sogo Medical Holdings, a Japanese pharmacy chain operator and B2B healthcare management platform.
Q&A: Zenysis Technologies' Jonathan Stambolis
Zenysis Technologies develops artificial intelligence-enabled systems that help governments improve healthcare management. CEO Jonathan Stambolis explains how demand has increased in response to COVID-19
Portfolio: Navis Capital Partners and Hanoi French Hospital
Navis Capital Partners has taken a boutique private hospital to a new level of competence and professionalism just in time for the biggest healthcare emergency in living memory
US, India pharma company Bugswork raises $7.5m
Bugworks Research, a pharmaceutical company with operations in India, has raised $7.5 million in a funding round led by existing investors University of Tokyo Edge Capital (UTEC) and Global Brain.
Akeso Biopharma trades up after $333m Hong Kong IPO
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO.